Compound Global Advisors LLC Acquires Shares of 1,700 IQVIA Holdings Inc. (NYSE:IQV)

Compound Global Advisors LLC acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 1,700 shares of the medical research company's stock, valued at approximately $334,000.

A number of other institutional investors also recently made changes to their positions in IQV. Capital Performance Advisors LLP bought a new position in shares of IQVIA during the 3rd quarter valued at $27,000. Synergy Asset Management LLC bought a new position in shares of IQVIA during the 4th quarter valued at $33,000. Avior Wealth Management LLC grew its holdings in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock valued at $38,000 after purchasing an additional 87 shares during the last quarter. Assetmark Inc. grew its holdings in shares of IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company's stock valued at $54,000 after purchasing an additional 196 shares during the last quarter. Finally, UMB Bank n.a. grew its holdings in shares of IQVIA by 74.4% during the 3rd quarter. UMB Bank n.a. now owns 232 shares of the medical research company's stock valued at $55,000 after purchasing an additional 99 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Stifel Nicolaus reduced their target price on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a report on Friday, February 7th. Stephens assumed coverage on shares of IQVIA in a report on Friday, December 20th. They issued an "overweight" rating and a $250.00 price target on the stock. UBS Group cut their price target on shares of IQVIA from $260.00 to $255.00 and set a "buy" rating on the stock in a report on Friday, February 7th. The Goldman Sachs Group cut their price target on shares of IQVIA from $280.00 to $250.00 and set a "buy" rating on the stock in a report on Friday, November 1st. Finally, JPMorgan Chase & Co. cut their price target on shares of IQVIA from $279.00 to $240.00 and set an "overweight" rating on the stock in a report on Tuesday, November 5th. Five equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, IQVIA currently has a consensus rating of "Moderate Buy" and an average target price of $251.67.

IQVIA Stock Down 1.2 %

NYSE IQV traded down $2.40 during trading hours on Friday, reaching $193.65. 1,527,608 shares of the company's stock traded hands, compared to its average volume of 1,398,820. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The firm has a market cap of $35.15 billion, a PE ratio of 25.82, a PEG ratio of 2.25 and a beta of 1.48. The firm has a 50-day simple moving average of $200.59 and a 200 day simple moving average of $218.51. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.81.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.81 EPS for the current fiscal year.

Insider Activity at IQVIA

In other news, Director John G. Danhakl acquired 1,275 shares of IQVIA stock in a transaction on Tuesday, December 3rd. The stock was acquired at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the purchase, the director now owns 1,275 shares in the company, valued at $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.